Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Moodys
McKesson
Medtronic
Merck

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

NEXPLANON Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Nexplanon, and when can generic versions of Nexplanon launch?

Nexplanon is a drug marketed by Organon Usa Inc and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and five patent family members in thirty-four countries.

The generic ingredient in NEXPLANON is etonogestrel. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the etonogestrel profile page.

DrugPatentWatch® Generic Entry Outlook for Nexplanon

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for NEXPLANON
Drug Prices for NEXPLANON

See drug prices for NEXPLANON

Recent Clinical Trials for NEXPLANON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kenya Medical Research InstitutePhase 4
Eastern Virginia Medical SchoolPhase 4
CONRADPhase 4

See all NEXPLANON clinical trials

Pharmacology for NEXPLANON
Drug ClassProgestin

US Patents and Regulatory Information for NEXPLANON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Usa Inc NEXPLANON etonogestrel IMPLANT;IMPLANTATION 021529-002 May 31, 2011 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Organon Usa Inc NEXPLANON etonogestrel IMPLANT;IMPLANTATION 021529-002 May 31, 2011 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Organon Usa Inc NEXPLANON etonogestrel IMPLANT;IMPLANTATION 021529-002 May 31, 2011 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Organon Usa Inc NEXPLANON etonogestrel IMPLANT;IMPLANTATION 021529-002 May 31, 2011 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for NEXPLANON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0303306 29/1999 Austria ⤷  Try it Free PRODUCT NAME: ETONOGESTREL; NAT. REGISTRATION NO/DATE: 1-22964 19990330; FIRST REGISTRATION: NL 21168 19980825
0303306 C980027 Netherlands ⤷  Try it Free PRODUCT NAME: ETONOGESTREL; REGISTRATION NO/DATE: RVG 21168 19980825
0303306 099C0041 Belgium ⤷  Try it Free PRODUCT NAME: ETONOGESTREL; NATL. REGISTRATION NO/DATE: 52 IS 296 F 14 19990531; FIRST REGISTRATION: NL RVG 21168 19980825
0303306 SPC/GB99/044 United Kingdom ⤷  Try it Free PRODUCT NAME: ETONOGESTREL; REGISTERED: NL RGV21168 19980825; UK 00065/0161 19990609
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Colorcon
McKesson
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.